Filtered By:
Specialty: General Medicine
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 1009 results found since Jan 2013.

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
Introduction The world is undergoing a demographic transition to an older population. Preventive healthcare has reduced the burden of chronic illness at younger ages but there is limited evidence that these advances can improve health at older ages. Statins are one class of drug with the potential to prevent or delay the onset of several causes of incapacity in older age, particularly major cardiovascular disease (CVD). This paper presents the protocol for the STAtins in Reducing Events in the Elderly (STAREE) trial, a randomised double-blind placebo-controlled trial examining the effects of statins in community dwelling o...
Source: BMJ Open - April 3, 2023 Category: General Medicine Authors: Zoungas, S., Curtis, A., Spark, S., Wolfe, R., McNeil, J. J., Beilin, L., Chong, T. T.-J., Cloud, G., Hopper, I., Kost, A., Nelson, M., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A., Ward, S. A., Wierzbicki, A., On behalf of STAREE investigator group Tags: Open access, Cardiovascular medicine Source Type: research

Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O ’CAFÉ trial)
Management of adults with atrial fibrillation (AF) or atrial flutter in the emergency department (ED) includes rate reduction, cardioversion, and stroke prevention. Different approaches to these components of ...
Source: Trials - March 31, 2023 Category: General Medicine Authors: David R. Vinson, Adina S. Rauchwerger, Chandu A. Karadi, Judy Shan, E. Margaret Warton, Jennifer Y. Zhang, Dustin W. Ballard, Dustin G. Mark, Erik R. Hofmann, Dale M. Cotton, Edward J. Durant, James S. Lin, Dana R. Sax, Luke S. Poth, Stephen H. Gamboa, Me Tags: Study protocol Source Type: research

Prevalence and clinical characteristics of atrial fibrillation in hospitalized patients with coronary artery disease and hypertension: a cross-sectional study from 2008 to 2018
CONCLUSIONS: AF is highly prevalent among patients with HT-CAD. Patients with both HT-CAD and AF have a higher prevalence of cardiovascular-related comorbidities, low BP control rate, and low use of oral anticoagulation.PMID:36914935 | DOI:10.1097/CM9.0000000000002471
Source: Chinese Medical Journal - March 14, 2023 Category: General Medicine Authors: Qian Xin Sijin Zhang Chi Wang Siyu Yao Cuijuan Yun Yizhen Sun Ziwei Hou Miao Wang Maoxiang Zhao Lu Tian Yanjie Li Zekun Feng Hao Xue Source Type: research

Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature
J Natl Med Assoc. 2023 Mar 5:S0027-9684(23)00034-2. doi: 10.1016/j.jnma.2023.02.008. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most prevalent arrhythmia in the United States and is responsible for 1 in 7 ischemic strokes. While anticoagulation is effective at preventing strokes, prior work has highlighted significant disparities in anticoagulation prescribing. Furthermore, racial, ethnic, sex, and socioeconomic disparities in AF outcomes have been described. As such, we aimed to review recent data on disparities with respect to anticoagulation for AF published between January 2018 and February 2021. The...
Source: Journal of the National Medical Association - March 7, 2023 Category: General Medicine Authors: Danielle J Daly Utibe R Essien Marcela G Del Carmen Benjamin Scirica Adam N Berman Jennifer Searl Como Jason H Wasfy Source Type: research

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives
Chin Med J (Engl). 2023 Feb 21. doi: 10.1097/CM9.0000000000002057. Online ahead of print.ABSTRACTThe clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and all-cause mortality benefit of PCSK9i remains inconclusive, current cholesterol management guidelines have been modified toward more aggressive goals for lowering low-density lipoprotein cholesterol (LDL-C). Consequently, the emerging ...
Source: Chinese Medical Journal - February 22, 2023 Category: General Medicine Authors: Xin Zhou Ziping Li Hangkuan Liu Yongle Li Dong Zhao Qing Yang Source Type: research